Trial: RV262
Phase: I
Start Date: September 2010
Sponsor, funder, developer: NIAID
Total participants: 92
Vaccine(s): Prime: PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Boost: MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL)
Clade: A, B, C, D, E